Login to Your Account

Winning orphan drug status for a second preclinical cancer therapy is "small but important progress" for Nanosmart Pharmaceuticals Inc., President James Smith told BioWorld Today.
Dauntless Pharmaceuticals Inc. had a smooth initial take-off, fueled by a $12 million series A supporting a single asset, and that's just the way the San Diego-based company and backer Sofinnova Ventures plan to keep rolling off the runway.
Astrazeneca plc spinout Entasis Therapeutics Inc. has come in from the cold with a portfolio of drugs that previously resided in the pharma's anti-infectives pipeline and a fistful of cash from its erstwhile parent.
More Newco News Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: